- 询价
- 2026年06月09日
15 年金牌会员
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
源叶生物 十万种现货试剂速发，品质稳、品类全，实验不再等！Takara 秋促来袭，提取+反转录+定量套装仅 1200 元abinScience 体内级抗体 全年锁价 低至 ￥1200阿拉丁 22万+ 科研级产品现货速发，品质严控、科研无忧- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 生长状态：
贴壁生长
- 库存：
大量
- 年限：
fetus, 20 days gestation
- 相关疾病：
其他疾病
- ATCC Number：
CRL-2949™
- 细胞形态：
其他
- 器官来源：
大脑
- 运输方式：
冻存运输
- 物种来源：
褐鼠
- 是否是肿瘤细胞：
0
| Designations: | F98npEGFRvIII | ||
| Depositors: | R.F. Barth | ||
| Biosafety Level: | 2 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | adherent | ||
| Organism: | Rattus norvegicus | ||
| Morphology: | glial |
||
| Source: | Organ: brain Disease: undifferentiated malignant glioma Breed: CD Fischer |
||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Isolation: | Isolation date: April 2001 | ||
| Receptors: | Epidermal Growth Factor Receptor vIII (EGFRvIII), expressed (verified at ATCC ) | ||
| Tumorigenic: | YES | ||
| Age: | fetus, 20 days gestation | ||
| Comments: | Epidermal Growth Factor Receptor (EGFR)-expressing F98 glioma cells (F98EGFR ) were produced by transfecting F98 (ATCC CRL-2397 ) with an expression vector containing human EGFRvIII cDNA. EGFRvIII is a truncated extracellular mutant of the EGF receptor commonly found in glioblastomas that confers enhanced tumorigenic behavior. The receptors are very weakly phosphorylated. This cell line has been used for in vivo studies of molecular targeting of EGFRvIII in syngeneic Fischer rats [PubMed: 15671565]. | ||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: |
||
| Subculturing: | Protocol: Volumes used in this protocol are for 75 sq cm flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subcultivation ratio: A subcultivation ratio of 1:6 to 1:10 is recommended. Medium renewal: Every 2 to 3 days Note: If cells are cultured continuously, add 0.6 mg/ml G-418 to the complete growth medium for a passage about once a month. |
||
| Preservation: | Freeze medium: complete growth medium, 95%; DMSO, 5% liquid nitrogen vapor phase |
||
| Doubling Time: | about 17 hours | ||
| Related Products: | Recommended medium (without the additional serum described under ATCC Medium): ATCC 30-2002 Recommended serum: ATCC 30-2020 Phosphate-buffered saline: ATCC 30-2200 Cell culture tested DMSO: ATCC 4-X Parental Cell Line: F98 (CRL-2397) Also derived from F98 (CRL-2397) : CRL-2949 (F98EGFR |
||
| References: | 16173105: Yang W, et al. Development of a Syngeneic Rat Brain Tumor Model Expressing EGFRvIII and Its Use for Molecular Taregeting Studies with Monoclonal Antibody L8A4. Clin. Cancer Res. 11(1): 341-350, 2005. PubMed: 15671565 16173106: Yang W, et al. Convection enhanced delivery of boronated epidermal growth factor for molecular targeting of EGFR positive gliomas. Cancer Res. 62: 6552-6558, 2002. PubMed: 12438250 16173107: Barth RF, et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 62(11): 3159-3166, 2002. PubMed: 12036929 16173108: Wu G, et al. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. 5(1): 52-59, 2006. PubMed: 16432162. 16173109: Wu G, et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 13(4): 1260-1268, 2007. PubMed: 17317838 16173110: Yang W, et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin. Cancer Res. 14(3): 883-891, 2008. PubMed: 18245552 |
||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
询价记录
暂无询价记录
文献和实验相关实验
，在有些病例，永久性瞳孔膜淹没了过滤角，阻止眼液从过滤角通过静脉流走，眼内压升高就导致了上述症状和后遗症。 青光眼发生于WAG近交鼠群。连续兄妹交配到95代后，牛眼的发生率逐渐升高，F98代时，牛眼的发生率15.3%。 3．白内障（Cataract,ca）大鼠：病鼠出生后约14日龄眼睑睁开时，表现为晶状体混浊（常为二侧），混浊常见于晶状体的中央。病变晶状体比正常的小，呈磨茹状而不呈球状，混浊是晶状体蛋白变化的结果，而不是由于矿物质增加，视网膜可能正常，未见有任何糖尿病的迹象
9sMffkekXB4sNHvv7vvutpeWLrO//NLf2GOPL5F98YAbNRHkguTs7e23I6bPsgkHTbOZM2farKOOs23btslRRdkee2yJPfHkr23lyhX21f/2d3bHojvsTm3HHnu0Pf/i87ZixTIn8GulAb/yBz+0Y2bMsqt+8H2787bb7KQTZ9vqlSvtWRH6937g/Xb9gpusX2YhW3butKuvv86+8BeftZdfftlOPflke2HpUmnAV9nalWttZ1ePzEiY7eccWX+hKVB
技术资料暂无技术资料 索取技术资料
F98npEGFRvIII
询价
